MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2024 International Congress

    Effect Of Botulinum Toxin On Non-Motor Symptoms In Adult-Onset Idiopathic Focal Dystonia

    S. Mehta, R. Gupta, N. Balaini, S. Grover, V. Lal (Chandigarh, India)

    Objective: To assess the effect of Botulinum toxin on non-motor symptoms and quality of life in patients with adult-onset idiopathic focal dystonia. Background: A broad…
  • 2024 International Congress

    Real-World Diagnosis of Chronic Migraine in Patients With Cervical Dystonia Analyzed by Botulinum Neurotoxin Treatment Exposure: an Epidemiologic Perspective

    R. Rodriguez, S. Broner, G. Forde, C. Rhyne, M. Sadeghi, E. Yue, A. Ukah, K. Becker Ifantides, H. Sarva (Orlando, USA)

    Objective: Describe the real-world diagnosis, demographics, and clinical characteristics of chronic migraine (CM) in cervical dystonia (CD) patients stratified by botulinum neurotoxin (BoNT) treatment. Background:…
  • 2024 International Congress

    Comparison in Therapeutic Outcome of Ultrasound-Guided Botulinum Injections for Limb Spasticity Versus Dystonia

    G. Yahalom, M. Cohen, I. Israel, R. Eichel, Y. Schechter (Jerusalem, Israel)

    Objective: To compare the therapeutic efficacy of BT injections for spasticity and dystonia in the limbs. Background: Botulinum toxin (BT) shows promise in alleviating limb…
  • 2024 International Congress

    Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods

    G. Forde, A. Patel, K. Martinez, A. Mayadev, B. Brucker, T. Brown, Z. Ayyoub, R. Singh, M. Nelson, A. Ukah, I. Yushmanova, S. Battucci, K. Becker Ifantides, C. Rhyne (New Hyde Park, USA)

    Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…
  • 2024 International Congress

    Demographics of Botulinum toxin therapy population representative to demographics in Essex County, USA

    B. Puccio, Y. Xu, J. Acquaviva, E. Feinstein (Newark, USA)

    Objective: To describe and compare the demographics of patients receiving botulinum toxin therapy in a single movement disorder clinic to the broader surrounding community. Background:…
  • 2024 International Congress

    Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach

    M. Hildaria, D. Tunjungsari, A. Tiksnadi (Central Jakarta, Indonesia)

    Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…
  • 2023 International Congress

    Putting the patient’s voice at the venter: Tracking the impact of botulinum neurotoxin therapy for movement disorders using patient-reported outcomes

    S. Samadzadeh, V. Koska, J. Waskönig, PJ. Jouvenal, SGM. Meuth, HH. Hefter, PA. Albrecht (Düsseldorf, Germany)

    Objective: To investigate how patient reported outcomes (PROs) perform to document the effects of a botulinum neurotoxin (BONT) treatment of movement disorders in the clinical…
  • 2023 International Congress

    Dystonia Treatment With Injections Supplemented by TMS: the D-TWIST Study

    J. Frey, J. Yu, J. Lobo Lopes, L. Fanty, I. Malaty, A. Ramirez-Zamora, M. Wajid, J. Cagle, C. de Hemptinne, A. Wagle Shukla (Morgantown, USA)

    Objective: To evaluate the safety, feasibility, tolerability and effects of accelerated rTMS for treatment of cervical dystonia. Background: In a subgroup of patients with cervical…
  • 2023 International Congress

    Incidence of dysphagia and comorbidities in patients with cervical dystonia, analyzed by botulinum neurotoxin treatment exposure

    M. Sadeghi, A. Ukah, E. Yue, K. Becker Ifantides, N. Huang, J. Lee, R. Barbano (Irvine, USA)

    Objective: Describe real-world incidence of dysphagia and other comorbidities in adults with cervical dystonia (CD) treated and not treated with botulinum neurotoxin (BoNT). Background: Dysphagia…
  • 2023 International Congress

    Topical Botulinum-Toxin-like Alternatives: A Systematic Literature Review

    S. Maytharakcheep, O. Phokaewvarangkul, R. Bhidayasiri (bangkok, Thailand)

    Objective: To perform a systematic review exploring the relevant literature on BoNT and BoNT-like substances in topical form and clinical trials focusing on facial muscle…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley